Abbott Laboratories Stock Price, News & Analysis (NYSE:ABT)

$83.58
+0.35 (+0.42 %)
(As of 09/22/2019 04:00 PM ET)
Today's Range
$82.87
Now: $83.58
$83.88
50-Day Range
$81.93
MA: $84.66
$86.80
52-Week Range
$65.44
Now: $83.58
$88.76
Volume7.13 million shs
Average Volume3.91 million shs
Market Capitalization$147.72 billion
P/E Ratio29.02
Dividend Yield1.54%
Beta1.14
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryHealth Care Equipment
SectorMedical
CUSIP00282410
CIK1800
Phone224-667-6100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$30.58 billion
Cash Flow$4.8256 per share
Book Value$17.49 per share

Profitability

Net Income$2.37 billion

Miscellaneous

Employees103,000
Outstanding Shares1,767,400,000
Market Cap$147.72 billion
Next Earnings Date10/16/2019 (Confirmed)
OptionableOptionable

Receive ABT News and Ratings via Email

Sign-up to receive the latest news and ratings for ABT and its competitors with MarketBeat's FREE daily newsletter.


Abbott Laboratories (NYSE:ABT) Frequently Asked Questions

What is Abbott Laboratories' stock symbol?

Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."

How often does Abbott Laboratories pay dividends? What is the dividend yield for Abbott Laboratories?

Abbott Laboratories declared a quarterly dividend on Thursday, September 12th. Stockholders of record on Tuesday, October 15th will be given a dividend of $0.32 per share on Friday, November 15th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 1.53%. The ex-dividend date is Friday, October 11th. View Abbott Laboratories' Dividend History.

How were Abbott Laboratories' earnings last quarter?

Abbott Laboratories (NYSE:ABT) announced its quarterly earnings results on Wednesday, July, 17th. The healthcare product maker reported $0.82 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.80 by $0.02. The healthcare product maker had revenue of $7.98 billion for the quarter, compared to analyst estimates of $8 billion. Abbott Laboratories had a net margin of 9.36% and a return on equity of 17.26%. The business's revenue for the quarter was up 2.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.73 EPS. View Abbott Laboratories' Earnings History.

When is Abbott Laboratories' next earnings date?

Abbott Laboratories is scheduled to release their next quarterly earnings announcement on Wednesday, October 16th 2019. View Earnings Estimates for Abbott Laboratories.

How can I listen to Abbott Laboratories' earnings call?

Abbott Laboratories will be holding an earnings conference call on Wednesday, October 16th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What guidance has Abbott Laboratories issued on next quarter's earnings?

Abbott Laboratories issued an update on its FY19 earnings guidance on Wednesday, July, 17th. The company provided earnings per share guidance of $3.21-3.27 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.22.

What price target have analysts set for ABT?

18 Wall Street analysts have issued twelve-month price objectives for Abbott Laboratories' stock. Their forecasts range from $68.00 to $98.00. On average, they anticipate Abbott Laboratories' stock price to reach $85.94 in the next twelve months. This suggests a possible upside of 2.8% from the stock's current price. View Analyst Price Targets for Abbott Laboratories.

What is the consensus analysts' recommendation for Abbott Laboratories?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abbott Laboratories in the last year. There are currently 1 sell rating, 2 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Abbott Laboratories.

Has Abbott Laboratories been receiving favorable news coverage?

Headlines about ABT stock have been trending somewhat negative this week, according to InfoTrie. The research firm ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Abbott Laboratories earned a news impact score of -1.3 on InfoTrie's scale. They also gave media coverage about the healthcare product maker a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Abbott Laboratories.

Who are some of Abbott Laboratories' key competitors?

What other stocks do shareholders of Abbott Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Abbott Laboratories investors own include AbbVie (ABBV), AT&T (T), Johnson & Johnson (JNJ), CA (CA), Cisco Systems (CSCO), Micron Technology (MU), Pfizer (PFE), Verizon Communications (VZ), Intel (INTC) and BlackRock (BLK).

Who are Abbott Laboratories' key executives?

Abbott Laboratories' management team includes the folowing people:
  • Mr. Miles D. White M.B.A., Chairman & CEO (Age 64)
  • Mr. Robert B. Ford, Pres & COO (Age 45)
  • Mr. Brian B. Yoor, Exec. VP of Fin. & CFO (Age 49)
  • Mr. Hubert L. Allen, Exec. VP, Gen. Counsel & Sec. (Age 53)
  • Mr. Stephen R. Fussell, Exec. VP of HR (Age 62)

Who are Abbott Laboratories' major shareholders?

Abbott Laboratories' stock is owned by many different of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.39%), BlackRock Inc. (7.16%), BlackRock Inc. (7.16%), Northern Trust Corp (1.50%), Bank of New York Mellon Corp (1.25%) and Morgan Stanley (1.19%). Company insiders that own Abbott Laboratories stock include Alejandro D Wellisch, Andrew H Lane, Brian B Yoor, Brian J Blaser, Daniel Gesua Sive Salvadori, Daniel J Starks, Hubert L Allen, Jaime Contreras, Jared Watkin, John G Stratton, John M Capek, Joseph J Manning, Michael J Pederson, Miles D White, Randel William Woodgrift, Roger Bird, Sally E Blount, Sharon J Bracken and Stephen R Fussell. View Institutional Ownership Trends for Abbott Laboratories.

Which institutional investors are selling Abbott Laboratories stock?

ABT stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Bank of New York Mellon Corp, Primecap Management Co. CA, Westwood Holdings Group Inc., Morgan Stanley, UBS Asset Management Americas Inc., Waddell & Reed Financial Inc. and Poplar Forest Capital LLC. Company insiders that have sold Abbott Laboratories company stock in the last year include Brian B Yoor, Brian J Blaser, Daniel Gesua Sive Salvadori, Hubert L Allen, Jaime Contreras, Jared Watkin, John M Capek, Joseph J Manning, Michael J Pederson, Miles D White, Randel William Woodgrift, Roger Bird, Sally E Blount, Sharon J Bracken and Stephen R Fussell. View Insider Buying and Selling for Abbott Laboratories.

Which institutional investors are buying Abbott Laboratories stock?

ABT stock was acquired by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Vanguard Group Inc., BlackRock Inc., BlackRock Inc., Marshall Wace North America L.P., Thoroughbred Financial Services LLC, DekaBank Deutsche Girozentrale and Voleon Capital Management LP. Company insiders that have bought Abbott Laboratories stock in the last two years include Daniel J Starks, John G Stratton and Randel William Woodgrift. View Insider Buying and Selling for Abbott Laboratories.

How do I buy shares of Abbott Laboratories?

Shares of ABT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Abbott Laboratories' stock price today?

One share of ABT stock can currently be purchased for approximately $83.58.

How big of a company is Abbott Laboratories?

Abbott Laboratories has a market capitalization of $147.72 billion and generates $30.58 billion in revenue each year. The healthcare product maker earns $2.37 billion in net income (profit) each year or $2.88 on an earnings per share basis. Abbott Laboratories employs 103,000 workers across the globe.View Additional Information About Abbott Laboratories.

What is Abbott Laboratories' official website?

The official website for Abbott Laboratories is http://www.abbott.com/.

How can I contact Abbott Laboratories?

Abbott Laboratories' mailing address is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. The healthcare product maker can be reached via phone at 224-667-6100.


MarketBeat Community Rating for Abbott Laboratories (NYSE ABT)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  760 (Vote Outperform)
Underperform Votes:  623 (Vote Underperform)
Total Votes:  1,383
MarketBeat's community ratings are surveys of what our community members think about Abbott Laboratories and other stocks. Vote "Outperform" if you believe ABT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel